Area of research
Hematology · Genetics
Research interest
Research interests include Myeloproliferative Neoplasms: Diagnosis and Treatment, Multiple Myeloma Research and Treatments, Chronic Myeloid Leukemia Treatments, and Acute Myeloid Leukemia Research.
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies.
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis.
Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study
Ropeginterferon alfa-2b in 248 patients with polycythemia vera: Results from the italian cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV)
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
An atypical presentation of visceral leishmaniasis mimicking multiple myeloma relapse.
Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis